Choose your location

Choose your language

New
FibroScan^® GO

The state-of-the-art non-invasive solution for liver disease management, affordable to all.

Supported by 3,500+ peer reviewed publications and 160+ guidelines.

Not suitable for all practice organizations. Please contact Echosens to determine if FibroScan^® GO is the best fit for your practice needs.

Test your eligibility for FibroScan GO

An affordable solution…

Comprehensive and flexible pay-per-exam offer.

All services included.

…to assist in liver health management

Screening of at-risk patients for early intervention.

Simple, quick, non-invasive and painless examination.

Interpretation tools and calculation of clinical scores
to support in making instant medical decisions for patients.

Assists in monitoring staged progression of liver disease
which may lead to improved patient outcomes.

FibroScan® GO Brochure

A comprehensive solution at the point-of-care

Perform the examination with FibroScan^® and interpretation
to determine the fibrosis stage and the steatosis grade.

Calculate FIB-4 and combined scores.

Generate consolidated and personalized medical reports.

Consult and visualize the history of your patients’ results.

Discover the exam in video

Tried & Trusted

Without FibroScan^® technology, we felt that our patients would be missing an important service and that many patients with advanced liver disease and significant health risk would go unrecognized.

Darryn Potosky | MD. Capital Digestive Care Columbia, MD

Patients who get a FibroScan^® love the fact that they now have understandable parameters of their NAFLD and NASH, or even just their transient elastography or fibrosis score.

Robert Leventhal | MD. Naugatuck Valley Gastroenterology Consultants, LLC Prospect, CT

More testimonials

A complete solution including proactive and dedicated support

Assists with onsite installation and training.

Includes maintenance, annual calibration of probes and both software upgrades and updates.

Easy access to continuous training and users community with Echosens Academy.

Learn more

A state-of-the-art FibroScan^®

Quickly and easily assess liver stiffness using LSM by VCTE™ and CAP™ for liver fibrosis and steatosis management.^1,2,3

Learn more

Not suitable for all practice organizations. Please contact Echosens to determine if FibroScan^® GO is the best fit for your practice needs.

Equipment compatible with an S+ probe (sold separately).

The FibroScan^® 230 is intended to provide shear wave speed measurements and estimates of tissue stiffness as well as ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter) in internal structures of the body. The Shear wave speed and stiffness measurements may be used as an aid to clinical management of adult patients with liver disease. FibroScan^® 230 is indicated for non-invasive measurement in the liver of 50 Hz shear wave speed and estimates of stiffness as well as determining a 3.5 MHz ultrasound coefficient of attenuation (CAP: Controlled Attenuation Parameter). Shear wave speed, stiffness and CAP may be used as an aid to diagnosis and monitoring of adult patients with liver disease, as part of an overall assessment of the liver. Shear wave speed, stiffness and CAP may be used as an aid in the clinical management of pediatric patients with liver disease.

All personal and health data generated by the FibroScan^® GO solution is managed in compliance with HIPAA regulations. Data located on Echosens Cloud is managed by an ISO27001 certified organization.

1. Wong VW, et al. Noninvasive biomarkers in NAFLD and NASH – current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15(8):461-478.

2. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264.

3. Steadman R, et al. A health technology assessment of transient elastography in adult liver disease. Can J Gastroenterol. 2013;27(3):149-158.